GCM Partners, LLC v. Hipaaline Ltd.

CourtDistrict Court, N.D. Illinois
DecidedApril 19, 2021
Docket1:20-cv-06401
StatusUnknown

This text of GCM Partners, LLC v. Hipaaline Ltd. (GCM Partners, LLC v. Hipaaline Ltd.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
GCM Partners, LLC v. Hipaaline Ltd., (N.D. Ill. 2021).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

GCM PARTNERS, LLC, an Illinois limited ) liability company, ) ) Plaintiff, ) ) No. 20 C 6401 v. ) ) Judge Sara L. Ellis HIPAALINE LTD., a limited company of ) England and Wales, and EMILY ARIDA ) FISHER, ) ) Defendants. )

OPINION AND ORDER Plaintiff GCM Partners, LLC (“GCM”) provided telehealth services for medical cannabis patients using Defendant Hipaaline Ltd.’s (“Hipaaline”) Leafwell software platform. After Hipaaline indicated its intent to sever the parties’ relationship, GCM filed this lawsuit against Hipaaline and its CEO, Emily Arida Fisher, on October 28, 2020. GCM brings claims for violation of the Computer Fraud and Abuse Act (“CFAA”), 18 U.S.C. § 1030, and the Defend Trade Secrets Act, 18 U.S.C. § 1836 et seq., as well as for Hipaaline’s anticipatory and actual breaches of the parties’ agreement, Fisher’s tortious interference with contract, and tortious interference with prospective economic advantage. In conjunction with the filing of the complaint, GCM sought preliminary injunctive relief. After receiving briefing and holding hearings on the request,1 on November 23, 2020, the Court issued an Opinion and Order, in which it found that GCM satisfied the requirements for preliminary injunctive relief. Doc. 26. Pursuant to Federal Rule of Civil Procedure 65, for the duration of the litigation and pending further order of the Court, the Court enjoined and restrained Hipaaline from (a) disabling,

1 At the time that the Court considered GCM’s request for injunctive relief, only counsel for Hipaaline had entered an appearance in this case, although Fisher participated in the hearings. suspending, or otherwise removing GCM’s access to the Leafwell platform; (b) replacing GCM’s third-party payment processor, Bluepay, with its own payment processor and collecting patient payments from the Leafwell platform; and (c) violating any other provision of the parties’ agreement.2 Id. at 34–35.

On February 24, 2021, Hipaaline entered administration, a formal insolvency procedure, in the United Kingdom. That same day, the administrators sold certain of Hipaaline’s assets to Online MD Ltd. (“Online MD”), a company also controlled by Fisher. After GCM discovered that it no longer had access to the Leafwell platform and related software and that Hipaaline had entered into administration, GCM filed an emergency motion for issuance of a rule to show cause and a finding of contempt [57]. GCM also seeks modification of the preliminary injunction to directly prevent Fisher from taking certain actions [63]. The Court held evidentiary hearings on March 19 and April 2, 2021. Given the ongoing insolvency proceedings, the Court finds that it cannot take any action against Hipaaline, Online MD, or Fisher in her official capacities as a former Hipaaline director and officer or a current Online MD director and officer.

And while the Court concludes that the preliminary injunction extends to Fisher in her personal capacity for actions taken after Hipaaline entered administration, GCM has not met its burden to show that Fisher acted in contempt of the Court’s order.

2 The Court acknowledges that part (c) of the relief it ordered—precluding Hipaaline from violating any other provision of the parties’ agreement—violates Rule 65(d)(1)(C) by referring to another document to describe the restrained acts. Nonetheless, the other aspects of the Court’s preliminary injunction (parts (a) and (b)) remain valid. 2 BACKGROUND3 I. Pre-Suit Facts In 2017, Dr. George Gavrilos, a pharmacist, and Dr. Steven Salzman, a doctor of osteopathy, founded a brick-and-mortar medical clinic to treat medical cannabis patients in

Illinois. Gavrilos formed GCM in the fall of 2018 to accommodate out-of-state expansion. Fisher, who holds herself out as a medical cannabis marketing specialist, approached Gavrilos in May 2019, about expanding GCM’s practice into telehealth by working with Hipaaline, of which Fisher was the CEO and majority shareholder. Fisher proposed that GCM operate telehealth clinics in states with medical cannabis programs, with Hipaaline providing marketing and technological infrastructure. GCM agreed, and the parties began working together in October 2019 to offer telehealth evaluations for medical cannabis certifications through the Leafwell platform, expanding to twenty-one states over the next eight months. In July 2020, GCM and Hipaaline memorialized their business relationship in the Exclusive Marketing and Consultant Services Agreement (the “Agreement”), which reflected an

effective date of October 1, 2019. The parties agreed to an initial five-year term running from July 6, 2020, which would automatically renew for one-year terms thereafter. The Agreement allowed for termination at any time only for “a material breach by the other Party” and specified that a party could not terminate the Agreement merely “for convenience.” Doc. 1-1 at 30. The Agreement required mutual, written consent for any amendments, as well as written consent from the other party for any assignment or delegation of the Agreement, and provided that it bound the parties’ successors and assigns. Id. at 30.

3 The Court presumes familiarity with the facts set forth in its November 23, 2020 Opinion and Order, Doc. 26, and only briefly recounts those facts here. 3 In the Agreement, Hipaaline represented that it “own[ed] and ha[d] full rights to use for the purposes of this Agreement the domain name www.leafwell.co and subject matter appearing at that web address as of May 1, 2020” and agreed to provide GCM with a license to use the Leafwell platform. Id. at 28, 31, 38. Section 3.3 of the Agreement provided that GCM would

collect all patient payments. Id. at 25. The Agreement further provided that GCM would pay Hipaaline $450 per hour worked, which “represent[ed] the fair market value of the Marketing and Consultant Services” and was “not based on the value or volume of services generated by [Hipaaline] on behalf of [GCM].” Id. at 38. In the course of their dealings, however, GCM paid Hipaaline 40% of its net revenues instead of by the hour. Soon after the parties memorialized the Agreement, their relationship soured as Fisher attempted to assert more control over the Leafwell business. On October 16, 2020, Fisher notified GCM that Hipaaline was terminating the Agreement, effective immediately. She indicated that Hipaaline would honor the parties’ financial arrangements through the end of October to allow for a smooth transition. Hipaaline also served GCM with a formal notice of

breach of contract and termination that same day, indicating that it had terminated the Agreement for GCM’s alleged material breaches in (1) engaging a direct competitor of Hipaaline to provide substantially similar services GCM agreed Hipaaline would provide on an exclusive basis and (2) violating corporate practice of medicine rules by improperly splitting fees with its independent contractor physicians. After Hipaaline served its notice of termination, Fisher proposed a settlement in which Hipaaline would assume all overhead and engage medical providers directly and Gavrilos, Salzman, and Dr. Lewis Jassey, one of GCM’s independent contractors, would collect 15% of revenue derived from marketing partnerships they generated as well as a 6% equity interest in 4 the event of a sale of Hipaaline. Gavrilos rejected the proposal. GCM then formally responded to Hipaaline’s notice of termination by declaring that Hipaaline anticipatorily repudiated and breached the Agreement.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Griggs v. Provident Consumer Discount Co.
459 U.S. 56 (Supreme Court, 1982)
Blockowicz v. Williams
630 F.3d 563 (Seventh Circuit, 2010)
United States v. Zhen Zhou Wu
711 F.3d 1 (First Circuit, 2013)
United States v. Apex Oil Co., Inc.
579 F.3d 734 (Seventh Circuit, 2009)
Securities & Exchange Commission v. Homa
514 F.3d 661 (Seventh Circuit, 2008)
Duthie v. MATRIA HEALTHCARE, INC.
543 F. Supp. 2d 958 (N.D. Illinois, 2008)
In Re Trans World Airlines, Inc.
322 F.3d 283 (Third Circuit, 2003)
ADT LLC v. Northstar Alarm Services, LLC
853 F.3d 1348 (Eleventh Circuit, 2017)
Eli Lilly and Company v. Arla Foods USA, Inc.
893 F.3d 375 (Seventh Circuit, 2018)
Taggart v. Lorenzen
587 U.S. 554 (Supreme Court, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
GCM Partners, LLC v. Hipaaline Ltd., Counsel Stack Legal Research, https://law.counselstack.com/opinion/gcm-partners-llc-v-hipaaline-ltd-ilnd-2021.